D-0150-2017 Class II Terminated
FDA drug recall D-0150-2017 was initiated by Pfizer Inc. on Nov 7, 2016 and is designated Class II. Reason for recall: Superpotent The recall status is terminated (terminated May 1, 2020). Affected quantity: 2,666 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 30, 2016
- Initiation Date
- Nov 7, 2016
- Termination Date
- May 1, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2,666 bottles
Product description
LEVOXYL(R) (levothyroxine sodium tablets, USP), 200 mcg, 100 count bottles, Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620, NDC 60793-860-01
Reason for recall
Superpotent
Distribution pattern
Nationwide
Code information
16H21, Exp. 08/2017
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0150-2017
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.